A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total (VLA-008 CALM Ext)

Trial Profile

A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total (VLA-008 CALM Ext)

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs CVA 21 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms CALMext
  • Sponsors Viralytics
  • Most Recent Events

    • 07 Jun 2016 Combined results of parent and extension study assessing the dynamics of tumor response (n=70) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 13 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 17 Mar 2016 Results from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, according to a Viralytics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top